Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

Inclusion Criteria: * Cytologically or histologically confirmed chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), or multiple myeloma (MM). * Evidence of relapsed disease * Measurable disease * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 Exclusion Criteria: * Prior treatment with SNS-032 injection (previously known as BMS-387032) * Pregnant or breastfeeding * Unwilling to use an approved, effective means of contraception according to the study site's standards * Use of therapeutic anticoagulation agents * Prior allogeneic bone marrow transplantation * Prior chemotherapy, monoclonal antibodies, investigational agents, or radiation therapy within 21 days before the first dose; nitrosoureas and mitomycin are not permitted for at least 42 days before the first dose. * Prior pelvic radiation therapy or radiation to \> 25% of bone marrow reserve * Any other medical, psychological, or social condition that would contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures Please note: There are additional inclusion/exclusion criteria for this study. Please contact the study center for additional information and to determine if the patient meets all study criteria.